News
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Phase III INAVO120 study. These data showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback